Many cytokines are currently under investigation as potential target to improve cardiac
function and outcome in the setting of acute myocardial infarction (MI) or chronic heart failure …

Cardiovascular diseases are the leading cause of death worldwide. Research in the last two
decades has emphasized the inflammatory process as a key component in the …

Background No data from controlled trials exists regarding the inflammatory response in
patients with de novo heart failure (HF) complicating ST-elevation myocardial infarction …

Mortality in sepsis remains unacceptably high and attempts to modulate the inflammatory
response failed to improve survival. Previous reports postulated that the sepsis-triggered …

Randomized, placebo-controlled trial of the anti-tumor necro... : Critical Care Medicine
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment …

Background Interleukin-6 (IL-6) levels are upregulated in myocardial infarction. Recent data
suggest a causal role of the IL-6 receptor (IL-6R) in coronary heart disease. We evaluated if …

Van Tassell et al IL-1 and Heart Disease 1911 progression of coronary artery disease and
impaired function. Nevertheless, reports of an inflammatory response during heart disease …

Objective: To evaluate whether administration of afelimomab, an anti-tumor necrosis factor F
(ab′) 2 monoclonal antibody fragment, would reduce 28-day all-cause mortality in patients …

Objectives: To evaluate the safety, pharmacokinetics, and efficacy of human recombinant
interleukin-1 receptor antagonist (IL-lra) in the treatment of patients with sepsis syndrome …

Background ST‐segment–elevation myocardial infarction is associated with an intense
acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 …